Alemtuzumab Outcomes Over 9 Years in RRMS Patients With Highly Active Disease From CARE-MS I and II (TOPAZ)

T Ziemssen; AD Bass; R Berkovich; S Eichau; J Hobart; SF Hunter; V Limmroth; D Pelletier; C Pozzilli; S Schippling; BA Singer; L Sousa; A Traboulsee; BMJ Uittlehaag; Wijmeersch B Van; EM Poole; Z Choudhry; S Geertsen; N Daizadeh; G Comi

doi:10.1111/ene.14307

Alemtuzumab Outcomes Over 9 Years in RRMS Patients With Highly Active Disease From CARE-MS I and II (TOPAZ)

T Ziemssen
, AD Bass
, R Berkovich
, S Eichau
, J Hobart
, SF Hunter
, V Limmroth
, D Pelletier
, C Pozzilli
, S Schippling
, BA Singer
, L Sousa
, A Traboulsee
, BMJ Uittlehaag
, Wijmeersch B Van
, EM Poole
, Z Choudhry
, S Geertsen
, N Daizadeh
, G Comi

Peninsula Medical School

Research output: Contribution to conference › Conference paper (not formally published) › peer-review

Original language	English
DOIs	https://doi.org/10.1111/ene.14307
Publication status	Published - May 2020

Access to Document

10.1111/ene.14307

Cite this

Ziemssen, T., Bass, AD., Berkovich, R., Eichau, S., Hobart, J., Hunter, SF., Limmroth, V., Pelletier, D., Pozzilli, C., Schippling, S., Singer, BA., Sousa, L., Traboulsee, A., Uittlehaag, BMJ., Van, W. B., Poole, EM., Choudhry, Z., Geertsen, S., Daizadeh, N., & Comi, G. (2020). Alemtuzumab Outcomes Over 9 Years in RRMS Patients With Highly Active Disease From CARE-MS I and II (TOPAZ). https://doi.org/10.1111/ene.14307

@conference{cc4471cbbca64665bec953c18991dc1b,

title = "Alemtuzumab Outcomes Over 9 Years in RRMS Patients With Highly Active Disease From CARE-MS I and II (TOPAZ)",

author = "T Ziemssen and AD Bass and R Berkovich and S Eichau and J Hobart and SF Hunter and V Limmroth and D Pelletier and C Pozzilli and S Schippling and BA Singer and L Sousa and A Traboulsee and BMJ Uittlehaag and Van, \{Wijmeersch B\} and EM Poole and Z Choudhry and S Geertsen and N Daizadeh and G Comi",

year = "2020",

month = may,

doi = "10.1111/ene.14307",

language = "English",

}

Ziemssen, T, Bass, AD, Berkovich, R, Eichau, S, Hobart, J, Hunter, SF, Limmroth, V, Pelletier, D, Pozzilli, C, Schippling, S, Singer, BA, Sousa, L, Traboulsee, A, Uittlehaag, BMJ, Van, WB, Poole, EM, Choudhry, Z, Geertsen, S, Daizadeh, N & Comi, G 2020, 'Alemtuzumab Outcomes Over 9 Years in RRMS Patients With Highly Active Disease From CARE-MS I and II (TOPAZ)'. https://doi.org/10.1111/ene.14307

TY - CONF

T1 - Alemtuzumab Outcomes Over 9 Years in RRMS Patients With Highly Active Disease From CARE-MS I and II (TOPAZ)

AU - Ziemssen, T

AU - Bass, AD

AU - Berkovich, R

AU - Eichau, S

AU - Hobart, J

AU - Hunter, SF

AU - Limmroth, V

AU - Pelletier, D

AU - Pozzilli, C

AU - Schippling, S

AU - Singer, BA

AU - Sousa, L

AU - Traboulsee, A

AU - Uittlehaag, BMJ

AU - Van, Wijmeersch B

AU - Poole, EM

AU - Choudhry, Z

AU - Geertsen, S

AU - Daizadeh, N

AU - Comi, G

PY - 2020/5

Y1 - 2020/5

UR - https://www.webofscience.com/api/gateway?GWVersion=2&SrcApp=PARTNER_APP&SrcAuth=LinksAMR&KeyUT=WOS:000534616801252&DestLinkType=FullRecord&DestApp=ALL_WOS&UsrCustomerID=11bb513d99f797142bcfeffcc58ea008

U2 - 10.1111/ene.14307

DO - 10.1111/ene.14307

M3 - Conference paper (not formally published)

ER -

Alemtuzumab Outcomes Over 9 Years in RRMS Patients With Highly Active Disease From CARE-MS I and II (TOPAZ)

Access to Document

Other files and links

Cite this